These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 7069549)

  • 21. [Effect of 1 alpha-hydroxycholecalciferol (1 alpha-OH-D3) and eel calcitonin derivative in experimental renal osteodystrophy].
    Minatoguchi T
    Nihon Jinzo Gakkai Shi; 1982 Oct; 24(10):1157-71. PubMed ID: 7161947
    [No Abstract]   [Full Text] [Related]  

  • 22. The efficacy of calcifediol in renal osteodystrophy.
    Recker R; Schoenfeld P; Letteri J; Slatopolsky E; Goldsmith R; Brickman A
    Arch Intern Med; 1978 May; 138 Spec No():857-63. PubMed ID: 646574
    [No Abstract]   [Full Text] [Related]  

  • 23. 1,25(OH)2D3 and 25-OHD3 in the treatment of renal osteodystrophy: comparison of combined versus 1,25(OH)2D3 administration alone.
    Coen G; Taccone Gallucci M; Bonucci E; Ballanti P; Bianchi AR; Bianchini G; Matteucci MC; Mazzaferro S; Picca S; Taggi F; Cinotti GA; Casciani CU
    Miner Electrolyte Metab; 1983; 9(1):19-27. PubMed ID: 6687749
    [No Abstract]   [Full Text] [Related]  

  • 24. Calcium and phosphate metabolism in chronic renal failure, with particular reference to the effect of 1 alpha-hydroxyvitamin D3.
    Madsen S
    Acta Med Scand Suppl; 1980; 638():3-120. PubMed ID: 6929650
    [No Abstract]   [Full Text] [Related]  

  • 25. Dialysis bone disease in childhood: treatment with 25-hydroxycholecalciferol.
    Luciani JC; Meunier PJ; Dumas R
    Pediatr Res; 1979 Oct; 13(10):1105-8. PubMed ID: 503634
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of 1,25(OH)2-vitamin D3 to separate 'types' on renal osteodystrophy.
    Coburn JW; Brickman AS; Sherrard DJ; Singer FR; Wong EG; Baylink DJ; Norman AW
    Proc Eur Dial Transplant Assoc; 1977; 14():442-50. PubMed ID: 600961
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Parathormone, calcitonin, 25-hydroxycalciferol and bone histology in patients with chronic renal insufficiency].
    Kokot F; Kuska J; Sledziński Z; Białas B; Luciak M
    Z Gesamte Inn Med; 1979 Nov; 34(22):665-70. PubMed ID: 549299
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 25-hydroxycholecalciferol in the treatment of renal osteodystrophy in haemodialysed patients.
    Coen G; Taccone-Gallucci M; Bonucci E; Bianchini G; Gallucci G; Lucentini G; Matteucci MC; Picca S; Casciani CU
    Int J Artif Organs; 1979 Nov; 2(6):278-81. PubMed ID: 511368
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 1,25-dihydroxycholecalciferol in renal osteodystrophy. Epiphysiolysis--anticonvulsant therapy.
    Pierides AM; Ellis HA; Dellagrammatikas H; Scott JE; Norman AW
    Arch Dis Child; 1977 Jun; 52(6):464-72. PubMed ID: 879832
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased growth after long-term oral 1alpha,25-vitamin D3 in childhood renal osteodystrophy.
    Chesney RW; Moorthy AV; Eisman JA; Jax DK; Mazess RB; DeLuca HF
    N Engl J Med; 1978 Feb; 298(5):238-42. PubMed ID: 201843
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Spinal calcium changes with 1alpha-hydroxyvitamin D3.
    Dabek JT; Robinson BH; Naik RB; Al-Hiti K
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():147s-150s. PubMed ID: 606412
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A model for clinical research studies of renal osteodystrophy in children.
    Norman ME; Mazur A; Gruskin AB
    Arch Intern Med; 1978 May; 138 Spec No():866-8. PubMed ID: 646576
    [No Abstract]   [Full Text] [Related]  

  • 33. Prevention of metabolic bone disease in the pre-end-stage renal disease setting.
    Coburn JW; Elangovan L
    J Am Soc Nephrol; 1998 Dec; 9(12 Suppl):S71-7. PubMed ID: 11443772
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [1 alpha-hydroxycholecalciferol in treatment of renal osteodystrophy].
    Chalmers TM; Davie MW; Hunter JO; Szaz KF
    J Urol Nephrol (Paris); 1974 Dec; 80(12):981. PubMed ID: 4617778
    [No Abstract]   [Full Text] [Related]  

  • 35. Effect of alfacalcidol on renal bone disease in mild to moderate renal failure. Monitoring the calcium-phosphate product is important.
    McGregor MS; Rowe PA; Junor BJ
    BMJ; 1995 Jul; 311(6997):124; author reply 124-5. PubMed ID: 7613376
    [No Abstract]   [Full Text] [Related]  

  • 36. Renal osteodystrophy in children on CAPD: a prospective trial of 1-alpha-hydroxycholecalciferol therapy.
    Watson AR; Kooh SW; Tam CS; Reilly BJ; Balfe JW; Vieth R
    Child Nephrol Urol; 1988-1989; 9(4):220-7. PubMed ID: 3255485
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 1 alpha hydroxycholecalciferol and 25 hydroxycholecalciferol in renal bone disease.
    Fournier AE; Bordier PJ; Gueris J; Chanard J; Marie P; Ferriere C; Osario M; Bedrossian J; de Luca HF
    Proc Eur Dial Transplant Assoc; 1976; 12():227-36. PubMed ID: 935115
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of 1,25(OH)2D3 and 24,25(OH)2D3 in the long-term treatment of renal osteodystrophy.
    Muirhead N; Catto GR; Edward N; Fraser RA; O'Riordan JL; Papapoulos SE; Adami S
    Proc Eur Dial Transplant Assoc; 1980; 17():543-7. PubMed ID: 6972529
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Parenteral calcitriol for treatment of severe renal osteodystrophy in children with chronic renal insufficiency.
    Trachtman H; Gauthier B
    J Pediatr; 1987 Jun; 110(6):966-70. PubMed ID: 3585613
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of alfacalcidol on renal bone disease in mild to moderate renal failure. Questions remain over alfacalcidol's efficacy in preventing secondary hyperparathyroidism.
    Fournier A; Esper NE; Moriniere P; Oprisiu R; Marie A
    BMJ; 1995 Jul; 311(6997):124; author reply 124-5. PubMed ID: 7677873
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.